Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Aug 1112:00 PM PDT
-01:00 PM PDT
- Know exactly what to study, every day - Built by the GMAT Club community - 100% free, no sign-up needed
Aug 1410:00 AM IST
-10:00 PM IST
Start your journey with a fully customized action plan and work with a dedicated mentor to achieve a 735+ score.- Aug 18
08:30 AM PDT
-09:30 AM PDT
Strong applicants do not always write strong MBA essays. In this session, we break down 5 common MBA essay mistakes that can quietly weaken an otherwise competitive application. These are not beginner mistakes .... - Aug 18
10:00 AM PDT
-11:00 AM PDT
Is GMAT Quant really a math test? Many test takers approach GMAT Quant with one of two beliefs: either “I’m not a math person, so I’ll struggle,” or “I’m good at math, so Quant should be easy.” But the GMAT often surprises both groups. - Aug 18
10:00 AM PDT
-11:00 AM PDT
In this episode of the GMAT Ninja Podcast, Charles and Brian Prestia bring six of the wildest GMAT improvement stories they’ve seen across decades of teaching. 
Aug 2210:00 AM EDT
-01:00 PM EDT
Elite scores are possible when you enroll in a powerful GMAT course, taught live online + 6 months access to TTP OnDemand video courses included! Class starts Saturdays August 22, 2026 - Nov. 14, 2026, 10:00am-1:00pm EST
Aug 2211:00 AM EDT
-12:00 PM EDT
Top Scores Start with a Elite Online Prep Course. Enroll for 6 months of access to over 400 hours of GMAT video lessons AND 715+ Score Guarantee!
28 Jul 2026, 10:45
Kudos
Bookmarks
SKP220292
I’d say the obstacle in (E) is not the public’s unawareness itself. The obstacle is the pitfalls and uncertainty that the public does not yet fully appreciate.
The passage says gene therapy has great potential, but there are hazards and uncertainties ahead. Those hazards could block or delay mainstream acceptance once they become clearer.
(D) is only one example showing that the field is still uncertain: only one controlled study has been published. But (E) captures the broader obstacle the author points to: unknown or underappreciated risks surrounding gene therapy.
28 Jul 2026, 12:42
Kudos
Bookmarks
Hi SKP220292,
Your reading of the paragraph's structure is what's tripping you up, so let's re-read the fifth paragraph carefully. You've treated "the public may not appreciate the pitfalls" as a lead-in, and the three later facts as the real obstacles. But look at how the author frames each piece.
The paragraph opens: "Public controversy... is driven by several factors." Everything after that - the unappreciated pitfalls, the overly optimistic statements, the small patient count, the single controlled study - is a factor driving controversy, not a list of obstacles to bringing gene therapy to mainstream medicine. So the three items you liked are being reported as facts about the current state of the field, not as things standing in the way of adoption.
Now the exact wording of the question matters: it asks what the author anticipates as a possible obstacle to introduction to mainstream medicine. That word "anticipates" points forward. Look at the line: "...the former may not appreciate all the pitfalls and uncertainty that lie in the immediate future." The public grasps the potential but not the dangers - and you can't roll something out to people who don't understand its risks. That forward-looking gap is choice E.
Why D falls short: "only one controlled study has been published" is a present-day fact about how early the field is - a symptom of the controversy, not a barrier the author forecasts for public adoption. It answers "what's true right now," not "what could block introduction later."
A quick way to feel the difference:
- "Few people have test-driven the new car yet" - a fact about the present (like D).
- "Buyers don't yet realize the brakes can fail" - an obstacle to selling it to them (like E).
The question wants the second kind. That's why E is the answer.
Answer: E
Your reading of the paragraph's structure is what's tripping you up, so let's re-read the fifth paragraph carefully. You've treated "the public may not appreciate the pitfalls" as a lead-in, and the three later facts as the real obstacles. But look at how the author frames each piece.
The paragraph opens: "Public controversy... is driven by several factors." Everything after that - the unappreciated pitfalls, the overly optimistic statements, the small patient count, the single controlled study - is a factor driving controversy, not a list of obstacles to bringing gene therapy to mainstream medicine. So the three items you liked are being reported as facts about the current state of the field, not as things standing in the way of adoption.
Now the exact wording of the question matters: it asks what the author anticipates as a possible obstacle to introduction to mainstream medicine. That word "anticipates" points forward. Look at the line: "...the former may not appreciate all the pitfalls and uncertainty that lie in the immediate future." The public grasps the potential but not the dangers - and you can't roll something out to people who don't understand its risks. That forward-looking gap is choice E.
Why D falls short: "only one controlled study has been published" is a present-day fact about how early the field is - a symptom of the controversy, not a barrier the author forecasts for public adoption. It answers "what's true right now," not "what could block introduction later."
A quick way to feel the difference:
- "Few people have test-driven the new car yet" - a fact about the present (like D).
- "Buyers don't yet realize the brakes can fail" - an obstacle to selling it to them (like E).
The question wants the second kind. That's why E is the answer.
Answer: E
SKP220292
How does that make sense though? Public's awareness of the pitfalls of a treatment is a roadblock? Let's apply this to the real world for a second - since when would a pharma company for example think "oh does the public know the pitfalls of our new drug? if not, we cannot move to production". The entire point of RC is to understand the author's logic. I fail to see the logic here.
The treatment facing a future obstacle because say even within the next 3 years, we don't have a lot of clinical trials - now that is a logical obstacle. How can the general public's awareness or lack thereof of a drug or a method of treatment ever be relevant to the medical science community's ease of rolling that treatment out? You say "and you can't roll something out to people who don't understand its risks." - mate, that is categorically untrue. Why would or when have you known a drug company do necessary research to ensure the broader public is educated on the side effects of its drug before taking said drug to market - do they even take necessary efforts to educate the otherwise unaware public of the results of a clinical trial? Not really. Your logic does not convince me and I am sure wasn't part of the author's reasoning either. The author mentions the public's unawareness - but does not mention so to mean that said unawareness is what can possibly derail gene therapy's future, nope!
The treatment facing a future obstacle because say even within the next 3 years, we don't have a lot of clinical trials - now that is a logical obstacle. How can the general public's awareness or lack thereof of a drug or a method of treatment ever be relevant to the medical science community's ease of rolling that treatment out? You say "and you can't roll something out to people who don't understand its risks." - mate, that is categorically untrue. Why would or when have you known a drug company do necessary research to ensure the broader public is educated on the side effects of its drug before taking said drug to market - do they even take necessary efforts to educate the otherwise unaware public of the results of a clinical trial? Not really. Your logic does not convince me and I am sure wasn't part of the author's reasoning either. The author mentions the public's unawareness - but does not mention so to mean that said unawareness is what can possibly derail gene therapy's future, nope!
egmat
